Monoclonal antibody M195

Drug Profile

Monoclonal antibody M195

Alternative Names: Aclizumab; Anti-CD33 monoclonal antibody M195; KB 195; SMART M195; SMART M195 antibody; Zamyl™

Latest Information Update: 11 Sep 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Developer Nippon Organon; Nonindustrial source; PDL BioPharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myeloid leukaemia; Preleukaemia

Most Recent Events

  • 25 Aug 2002 Discontinued - Phase-I for Myeloid leukaemia in Japan (unspecified route)
  • 25 Aug 2002 Discontinued - Phase-II for Acute promyelocytic leukaemia in USA (unspecified route)
  • 25 Aug 2002 Discontinued - Phase-II for Preleukaemia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top